1. Home
  2. GME vs SCLXW Comparison

GME vs SCLXW Comparison

Compare GME & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GME
  • SCLXW
  • Stock Information
  • Founded
  • GME 1996
  • SCLXW N/A
  • Country
  • GME United States
  • SCLXW United States
  • Employees
  • GME N/A
  • SCLXW N/A
  • Industry
  • GME Electronics Distribution
  • SCLXW Biotechnology: Pharmaceutical Preparations
  • Sector
  • GME Consumer Discretionary
  • SCLXW Health Care
  • Exchange
  • GME Nasdaq
  • SCLXW Nasdaq
  • Market Cap
  • GME N/A
  • SCLXW N/A
  • IPO Year
  • GME 2002
  • SCLXW N/A
  • Fundamental
  • Price
  • GME $27.00
  • SCLXW $0.18
  • Analyst Decision
  • GME Sell
  • SCLXW
  • Analyst Count
  • GME 1
  • SCLXW 0
  • Target Price
  • GME $10.00
  • SCLXW N/A
  • AVG Volume (30 Days)
  • GME 5.4M
  • SCLXW 4.0K
  • Earning Date
  • GME 03-25-2025
  • SCLXW 03-07-2025
  • Dividend Yield
  • GME N/A
  • SCLXW N/A
  • EPS Growth
  • GME N/A
  • SCLXW N/A
  • EPS
  • GME 0.17
  • SCLXW N/A
  • Revenue
  • GME $4,334,000,000.00
  • SCLXW $55,152,000.00
  • Revenue This Year
  • GME N/A
  • SCLXW N/A
  • Revenue Next Year
  • GME N/A
  • SCLXW N/A
  • P/E Ratio
  • GME $159.05
  • SCLXW N/A
  • Revenue Growth
  • GME N/A
  • SCLXW 22.02
  • 52 Week Low
  • GME $9.95
  • SCLXW $0.18
  • 52 Week High
  • GME $64.83
  • SCLXW $0.18
  • Technical
  • Relative Strength Index (RSI)
  • GME 48.38
  • SCLXW N/A
  • Support Level
  • GME $25.60
  • SCLXW N/A
  • Resistance Level
  • GME $27.76
  • SCLXW N/A
  • Average True Range (ATR)
  • GME 0.99
  • SCLXW 0.00
  • MACD
  • GME 0.11
  • SCLXW 0.00
  • Stochastic Oscillator
  • GME 55.63
  • SCLXW 0.00

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: